STOCKHOLM, Sweden & PITTSBURGH--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (NASDAQ:DMYDY)(STO:DIAMB) announced today that it has received approval from the U.S. FDA to initiate a Phase I study in chronic pain using NP2, the company’s first drug candidate in its Nerve Targeting Drug Delivery System (NTDDS) gene therapy platform.
